Skip to content

Study · Systematic review · 2026

5 results

Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials.

Zhao S, Tian F, Yu L, Li Z, Hou J, Wei Y, Cui H, Cui S, Ma X

Internal and emergency medicine31 Mar 2026

PMID41917519 (opens in a new tab)DOI10.1007/s11739-026-04326-w (opens in a new tab)PepBankPUB-41917519
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with MASLD/MASH, tirzepatide significantly improved MASH resolution without worsening of fibrosis versus placebo.

    In plain wordsIn adults with fatty liver disease, tirzepatide cleared MASH without worse scarring more often than placebo in a pooled analysis.

    Peptide
    Tirzepatide
    Outcome
    IncreaseMASH resolution without worsening of fibrosis
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tirzepatide and resmetirom significantly improved MASH resolution without worsening of fibrosis and reduced hepatic steatosis.
    1 context sentence
    Summary · context
    Eligible randomized controlled trials (RCTs) were those that enrolled adults with MASLD/MASH and compared tirzepatide, lanifibranor, or resmetirom with placebo.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with MASLD/MASH, tirzepatide significantly reduced hepatic steatosis on MRI-PDFF versus placebo (mean difference -34.90%).

    In plain wordsIn adults with fatty liver disease, tirzepatide reduced liver fat on scans more than placebo in a pooled analysis.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHepatic steatosis by MRI-PDFF
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    mean difference
    −34.9%
    MRI-PDFF, tirzepatide vs placebo

    Source sentences

    Summary
    Tirzepatide (mean difference [MD] - 34.90% [95% CI: - 53.31 to - 16.49])
    1 context sentence
    Summary · context
    Eligible randomized controlled trials (RCTs) were those that enrolled adults with MASLD/MASH and compared tirzepatide, lanifibranor, or resmetirom with placebo.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with MASLD/MASH, tirzepatide significantly reduced serum ALT versus placebo (mean difference -30.90%).

    In plain wordsIn adults with fatty liver disease, tirzepatide lowered the liver enzyme ALT more than placebo in a pooled analysis.

    Peptide
    Tirzepatide
    Outcome
    DecreaseSerum ALT
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    ALT mean difference
    −30.9%
    tirzepatide vs placebo

    Source sentences

    Summary
    Tirzepatide significantly reduced serum aminotransferase levels (ALT: MD - 30.90%, p < 0.00001; AST: MD - 20.71%, p < 0.00001).
    1 context sentence
    Summary · context
    Eligible randomized controlled trials (RCTs) were those that enrolled adults with MASLD/MASH and compared tirzepatide, lanifibranor, or resmetirom with placebo.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with MASLD/MASH, tirzepatide significantly reduced serum AST versus placebo (mean difference -20.71%).

    In plain wordsIn adults with fatty liver disease, tirzepatide lowered the liver enzyme AST more than placebo in a pooled analysis.

    Peptide
    Tirzepatide
    Outcome
    DecreaseSerum AST
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    AST mean difference
    −20.71%
    tirzepatide vs placebo

    Source sentences

    Summary
    Tirzepatide significantly reduced serum aminotransferase levels (ALT: MD - 30.90%, p < 0.00001; AST: MD - 20.71%, p < 0.00001).
    1 context sentence
    Summary · context
    Eligible randomized controlled trials (RCTs) were those that enrolled adults with MASLD/MASH and compared tirzepatide, lanifibranor, or resmetirom with placebo.

Studies that did not test the peptide alone1

In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tirzepatide.

  1. 05HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    In adults with MASLD/MASH, gastrointestinal adverse events were frequently reported across the treatment arms of tirzepatide, lanifibranor and resmetirom.

    In plain wordsIn adults with fatty liver disease, digestive side effects were common across all three drugs studied, including tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Not applicableGastrointestinal adverse events across all arms
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Gastrointestinal adverse events were frequently reported across all treatment arms.
    1 context sentence
    Summary · context
    Eligible randomized controlled trials (RCTs) were those that enrolled adults with MASLD/MASH and compared tirzepatide, lanifibranor, or resmetirom with placebo.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.